Research.Patient.info

refractory, advanced gastro-oesophageal cancer research hub

1 indexed studies · 0 currently recruiting

ongoing, recruitingTherapeutic confirmatory (Phase III)
INTEGRATE IIb A Randomised Phase III Open Label Study of regorafenib + nivolumab vs standard chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)
This study is testing two medicines, regorafenib and nivolumab, against standard chemotherapy for advanced stomach or gullet cancer that hasn't responded to previous treatments. Researchers want to see if this new combination helps people live longer.
Austria · Germany · Italy